67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma

Neuroblastoma Clinical Trial

Official title:

67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk Neuroblastoma: A Multi-center, Dose-escalation, Open-label, Non-randomized, Phase 1-2a Theranostic Clinical Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04023331
• Other study ID #: CL04
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: August 18, 2020
• Est. completion date: December 2028

Study information

• Verified date: December 2023
• Source: Clarity Pharmaceuticals Ltd
• Contact: Clarity Pharmaceuticals
• Phone: +61 (0) 2 9209 4037
• Email: clinicaltrials[@]claritypharmaceuticals.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to evaluate the safety and efficacy of 67Cu-SARTATE in pediatric patients with high-risk neuroblastoma.

Description:

This is an 'adaptive trial'. The trial design uses the accumulating data from the ongoing trial to modify aspects of the trial (e.g. dose, number of treatments). The trial is also a 'personalised trial' as the interval between treatments and number of treatments is determined for each patient individually. This study is to be conducted in 2 phases, a dose escalation phase and a cohort expansion phase. Dose escalation will be completed using a modified 3+3 study design with up to 4 Cohorts of increasing doses in MBq/kg. Pre-defined Dose Limiting Toxicities will be monitored for 6 weeks post administration of 1 therapy cycle of 67Cu-SARTATE. Participants who demonstrate therapeutic benefit (defined as non progression as assessed by the Investigator using the International Neuroblastoma Response Criteria (INRC) guidelines) may be offered additional Therapy Cycles (each participant may receive a maximum of 4 Therapy Cycles in total). Cohort expansion will commence once either the Maximum Tolerated Dose (MTD) for a single administration of 67Cu-SARTATE is established, or Cohort 4 has been completed. The study will be expanded to enroll an additional 10 subjects who will receive at least 2 therapy cycles of 67Cu-SARTATE at the MTD dose level. Participants who demonstrate therapeutic benefit (defined as non progression as assessed by the Investigator using the INRC guidelines) may be offered additional Therapy Cycles (each participant may receive a maximum of 4 Therapy Cycles in total). The study also includes a long-term follow-up period to 36 months following the first dose of 67Cu-SARTATE, although in person study visits are not required.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 34
• Est. completion date: December 2028
• Est. primary completion date: December 2028
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

1. Participant is able and willing to provide informed consent (=18 years), or informed consent is obtained by the parent or legal guardian for minor participants, with the minor providing age appropriate assent, according to local law and regulations;

2. Life expectancy = 12 weeks;

3. Known high-risk neuroblastoma OR previously intermediate-risk neuroblastoma that has relapsed or progressed to high-risk, with failure to achieve complete response with standard therapy (defined as at least 4 cycles of aggressive multi-drug induction chemotherapy with or without radiation and surgery, or according to a standard high-risk treatment/neuroblastoma protocol), OR who are medically ineligible to receive standard treatment OR who are intolerant to standard treatment;

4. Adequate recovery from acute toxic effects of any prior therapy, as deemed by the Investigator or treating Sub-Investigator;

5. Adequate liver function as defined by the following laboratory values obtained within 28 days prior to administration of 64Cu-SARTATE: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3.0 x upper limit of normal (ULN);

6. Adequate renal function;

7. Adequate laboratory parameters: Absolute neutrophil count > 1.0 x 10 9/L; Platelet count > 50 x 10 9/L; Total bilirubin <1.5 x ULN;

8. Karnofsky or Lansky performance status =50;

9. All participants must have a hematopoietic stem cell product available (minimum CD34+ cell dose is =2 x 10 6 cells/kg);

10. Sexually active participants of reproductive potential must practice an effective method of birth control while participating on this study, to avoid possible damage to the fetus. Abstinence is considered acceptable;

11. 64Cu-SARTATE uptake on the 4 hour scan (SUVmax) of any lesion equal to or higher than that of the liver in order to move on to the therapy phase of the study.

Exclusion Criteria:

1. Participants with disease of any major organ system that would compromise their ability to tolerate therapy, as deemed by the Investigator or treating Sub-Investigator;

2. Any other active malignancy, or a history of prior malignancy within the past 3 years;

3. History of cardiac failure as evidenced by: dyspnea at rest, exercise intolerance, oxygen requirement, clinically significant cardiac dysfunction;

4. Planned administration of chemotherapy, anti-cancer cytokine therapy, immunotherapy or radiotherapy within 2 weeks prior to the administration of 64Cu-SARTATE;

5. Administration of therapeutic dose of 131I-MIBG within 8 weeks prior to the administration of 64Cu-SARTATE;

6. External beam radiation therapy (EBRT) to both kidneys or a single functioning kidney within 12 months prior to the administration of 64Cu-SARTATE;

7. Administration of any investigational agents within 21 days prior to administration of 64Cu-SARTATE;

8. Treatment with long acting somatostatin analogues (administered within 28 days prior to the administration of 64Cu-SARTATE), or short acting somatostatin analogues (administered within 24 hours prior to the administration of 64Cu-SARTATE);

9. Known sensitivity or allergy to somatostatin analogues;

10. Previous peptide receptor radionuclide therapy (PRRT);

11. Female participants who are pregnant or lactating;

12. Participants who are on hemodialysis;

13. QTc interval = 0.45 seconds as measured by Screening ECG;

14. Participants with uncontrolled infection(s);

15. Any medical condition which the Investigator feels may interfere with the procedures or evaluations of the study;

16. Participants 12 months and younger will be excluded from cohorts where the planned single or cumulative administered activity is modelled to deliver a radiation dose to the marrow that exceeds 2 Gy.

Related Conditions & MeSH terms

• Neuroblastoma
• Refractory Neuroblastoma
• Relapsed Neuroblastoma

Intervention

Drug:
• 67Cu-SARTATE
67Cu-labelled MeCOSar-Tyr3-octreotate
• 64Cu-SARTATE
64Cu-labelled MeCOSar-Tyr3-octreotate

Locations

Country	Name	City	State
United States	Medical University of South Carolina	Charleston	South Carolina
United States	Cincinnati Children's Hospital Medical Centre	Cincinnati	Ohio
United States	University of Texas Southwestern Medical Centre	Dallas	Texas
United States	MD Anderson Cancer Center	Houston	Texas
United States	University of Wisconsin	Madison	Wisconsin
United States	Memorial Sloan Kettering Cancer Center	New York	New York
United States	Phoenix Children's Hospital	Phoenix	Arizona
United States	Washington University School of Medicine	Saint Louis	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
Clarity Pharmaceuticals Ltd

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum Tolerated Dose (MTD) of 67Cu-SARTATE	MDT as determined by cohort observations of Dose Limiting Toxicities	6 weeks
Primary	Safety and tolerability of Cu-67 SARTATE using Common Terminology Criteria for Adverse Events (CTCAE)	Safety will be assessed via vital signs, pathology tests (hematology, biochemistry, urinalysis, coagulation), physical examinations, electrocardiograms (ECGs) and spontaneous adverse event (AE) reporting.	Up to 36 months
Primary	Safety and tolerability of Cu-64 SARTATE using CTCAE	Safety will be assessed via vital signs, pathology tests (hematology, biochemistry, urinalysis, coagulation), physical examinations, ECGs and spontaneous AE reporting.	Up to 36 months
Primary	Overall response rate	As assessed by international neuroblastoma response criteria (INRC).	Up to 12 months
Primary	Best response	As assessed by international neuroblastoma response criteria (INRC).	6 to 8 weeks post final therapy